Biomarker for Patient Stratification for Treatment of Cognitive Impairment in Patients with Vascular Contributions to Cognitive Impairment

Case ID:

This technology has found a serum biomarker that is efficacious in stratifying patients with vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD). This biomarker was able to indicate patients with high levels of VCID that are well suited for treatment with angiotensin peptides.

Worldwide, an estimated 50 million people are living with some form of dementia but much is still unknown its causes, how to properly diagnose it, and especially how to treat it. Research through clinical studies is therefore imperative to begin to understand this disorder that affects so many people. This technology allows for patients to be selected for clinical studies based on the prevalence of the biomarker in their plasma. Blood biomarkers, when proven effective for detection of a certain disease, are an easy method for determining whether an individual meets the requirements for a certain study of that disease. Because this biomarker helps to select better candidates for the clinical study, the researchers are able to more effectively create a treatment for vascular contributions to cognitive impairment dementia (VCID).


  • Protein biomarker for vascular cognitive impairment dementia
  • Patient stratification for clinical studies for dementia treatment 
  • Diagnostic method for VCID


  • Easy use
  • Cost-effective
  • Efficient
Patent Information:
Contact For More Information:
Garrett Edmunds
Licensing Manager, UAHS-TLA
The University of Arizona
Lead Inventor(s):
Meredith Hay
John Konhilas
Christina Hoyer-Kimura
Thomas Beach
Geidy Serrano
Eric Reiman